Spots Global Cancer Trial Database for liposarcoma
Every month we try and update this database with for liposarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | NCT00579501 | Liposarcoma,Myx... | Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT02451943 | Soft Tissue Sar... | Olaratumab Doxorubicin Placebo | 18 Years - | Eli Lilly and Company | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| BTX-A51 in Patients With Liposarcoma | NCT06414434 | Liposarcoma Recurrent Lipos... Metastatic Lipo... Unresectable Li... MDM2 Gene Ampli... | BTX-A51 | 18 Years - | Dana-Farber Cancer Institute | |
| Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum | NCT02587169 | Retroperitoneal... Retroperitoneal... Chondrosarcoma | Nilotinib-adria... | 18 Years - 70 Years | Broto, Javier Martín, M.D. | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | NCT02451943 | Soft Tissue Sar... | Olaratumab Doxorubicin Placebo | 18 Years - | Eli Lilly and Company | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma | NCT01841047 | Liposarcoma | Radiotherapy | 18 Years - | Institut Bergonié | |
| A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma | NCT01692678 | Advanced or Met... | Trabectedin Dacarbazine | 15 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | NCT00949325 | Sarcoma | temsirolimus pl... | 1 Year - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma | NCT01883518 | Sarcoma Neoplasms, Conn... | Autologous dend... | 18 Years - | N.N. Petrov National Medical Research Center of Oncology | |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | NCT05094804 | Cancer Tumor, Solid Malignant Neopl... Metastatic Canc... Advanced Solid ... Non Small Cell ... Melanoma Head and Neck S... Leiomyosarcoma Liposarcoma | OR2805 Cemiplimab Docetaxel | 18 Years - | OncoResponse, Inc. | |
| Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | NCT00579501 | Liposarcoma,Myx... | Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | NCT02275286 | Liposarcoma, My... Sarcoma, Soft T... Leiomyosarcoma Liposarcoma Pleomorphic Lip... | Trabectedin Radiotherapy | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Sarcoma | pegfilgrastim doxorubicin hyd... ifosfamide pegylated lipos... conventional su... fludeoxyglucose... | 16 Years - | Masonic Cancer Center, University of Minnesota | |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | NCT03899805 | Sarcoma Liposarcoma Leiomyosarcoma Undifferentiate... | Eribulin Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | NCT04906876 | Sarcoma Soft Tissue Sar... Metastatic Sarc... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma | Gemcitabine Docetaxel 9-ING-41 | 10 Years - | Brown University | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | NCT05116800 | Soft Tissue Sar... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma Osteosarcoma Ewing Sarcoma o... | Gemcitabine 9-ING-41 Docetaxel | 10 Years - | Brown University | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | NCT02275286 | Liposarcoma, My... Sarcoma, Soft T... Leiomyosarcoma Liposarcoma Pleomorphic Lip... | Trabectedin Radiotherapy | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| The FGF/FGFR Signalling Pathway: | NCT03303885 | Liposarcoma | 18 Years - | Centre Hospitalier Universitaire de Nice | ||
| Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery | NCT02249949 | Liposarcoma | efatutazone | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients | NCT06039046 | Liposarcoma | 18 Years - | Power Life Sciences Inc. | ||
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | NCT06239272 | Non-rhabdomyosa... Adipocytic Neop... Liposarcoma | Surgical resect... Proton beam rad... Pazopanib Ifosfamide Doxorubicin Selinexor | - 30 Years | St. Jude Children's Research Hospital | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma | NCT02247544 | Liposarcoma Leiomyosarcoma | Trabectedin | 18 Years - | Italian Sarcoma Group | |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors | NCT00413322 | Tumor | belinostat 5-Fluorouracil ... | 18 Years - | Valerio Therapeutics | |
| Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | NCT02343172 | Liposarcoma | HDM201 LEE011 | 18 Years - | Novartis | |
| Detection of Circulating Tumor Cells in Patients With Sarcomas | NCT02983539 | Leiomyosarcoma Pleomorphic Lip... Synovial Sarcom... Liposarcoma | 18 Years - 70 Years | AC Camargo Cancer Center | ||
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | NCT04031677 | Retroperitoneal... Liposarcoma Leiomyosarcoma | Surgery Preoperative ch... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | NCT01209598 | Sarcoma Liposarcoma | Palbociclib 200... Palbociclib 125... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | NCT02571829 | Liposarcoma Soft Tissue Sar... | ribociclib | 18 Years - | Hadassah Medical Organization | |
| Bevacizumab and Radiation Therapy for Sarcomas | NCT00356031 | Soft Tissue Sar... Fibrous Histioc... Liposarcoma Leiomyosarcoma Fibrosarcoma Synovial Sarcom... | Bevacizumab Radiation Thera... Surgery | 18 Years - | Massachusetts General Hospital | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation | NCT00132704 | Ovarian Neoplas... Colorectal Neop... Melanoma Small Cell Lung... Liposarcoma | Ionizing radiat... Ionizing radiat... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | NCT03361436 | Liposarcoma Malignant Abdom... Malignant Retro... Malignant Scrot... Malignant Solid... Malignant Sperm... | Eribulin Mesyla... Intensity-Modul... Laboratory Biom... Quality-of-Life... Questionnaire A... Therapeutic Con... | 12 Years - | OHSU Knight Cancer Institute | |
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma | NCT02247544 | Liposarcoma Leiomyosarcoma | Trabectedin | 18 Years - | Italian Sarcoma Group | |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin | NCT03773510 | Leiomyosarcoma Liposarcoma Synovial Sarcom... | Trabectedin dis... Trabectedin con... | 18 Years - | Italian Sarcoma Group | |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | NCT04557449 | Liposarcoma CRC Prostate Cancer Breast Neoplasm... Adenocarcinoma ... Solid Tumors | PF-07220060 Letrozole Fulvestrant Midazolam Enzalutamide | 18 Years - | Pfizer | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | NCT02343172 | Liposarcoma | HDM201 LEE011 | 18 Years - | Novartis | |
| ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma | NCT05116683 | Leiomyosarcoma Liposarcoma | ATX-101 | 18 Years - 99 Years | Columbia University | |
| Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | NCT02978859 | Liposarcoma Metastatic Lipo... | MGCD516 | 18 Years - | Columbia University | |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | NCT02584309 | Sarcoma, Soft T... Soft Tissue Sar... Undifferentiate... Leiomyosarcoma Liposarcoma Synovial Sarcom... Myxofibrosarcom... Angiosarcoma Fibrosarcoma Malignant Perip... Epithelioid Sar... | Dexrazoxane Doxorubicin | 18 Years - | Washington University School of Medicine | |
| PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | NCT01209598 | Sarcoma Liposarcoma | Palbociclib 200... Palbociclib 125... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab | NCT06116578 | Cancer | Pembrolizumab Pembrolizumab a... Pembrolizumab a... | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | NCT05103631 | Liver Cell Carc... Solid Tumor Wilms Tumor Malignant Rhabd... Yolk Sac Tumor Rhabdomyosarcom... Liposarcoma Embryonal Sarco... | CATCH T cells | 18 Years - | Baylor College of Medicine | |
| Detection of Circulating Tumor Cells in Patients With Sarcomas | NCT02983539 | Leiomyosarcoma Pleomorphic Lip... Synovial Sarcom... Liposarcoma | 18 Years - 70 Years | AC Camargo Cancer Center | ||
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | NCT02923778 | Leiomyosarcoma Liposarcoma Sarcoma G2 Sarcoma G3 Soft Tissue Sar... Soft Tissue Sar... Stage I Soft Ti... Stage II Soft T... Undifferentiate... | Biopsy Biospecimen Col... Magnetic Resona... Radiation Thera... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | NCT06239272 | Non-rhabdomyosa... Adipocytic Neop... Liposarcoma | Surgical resect... Proton beam rad... Pazopanib Ifosfamide Doxorubicin Selinexor | - 30 Years | St. Jude Children's Research Hospital | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | NCT00949325 | Sarcoma | temsirolimus pl... | 1 Year - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | NCT05094804 | Cancer Tumor, Solid Malignant Neopl... Metastatic Canc... Advanced Solid ... Non Small Cell ... Melanoma Head and Neck S... Leiomyosarcoma Liposarcoma | OR2805 Cemiplimab Docetaxel | 18 Years - | OncoResponse, Inc. | |
| Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | NCT00579501 | Liposarcoma,Myx... | Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | NCT06239272 | Non-rhabdomyosa... Adipocytic Neop... Liposarcoma | Surgical resect... Proton beam rad... Pazopanib Ifosfamide Doxorubicin Selinexor | - 30 Years | St. Jude Children's Research Hospital | |
| A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | NCT02571829 | Liposarcoma Soft Tissue Sar... | ribociclib | 18 Years - | Hadassah Medical Organization | |
| Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery | NCT02249949 | Liposarcoma | efatutazone | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | NCT02343172 | Liposarcoma | HDM201 LEE011 | 18 Years - | Novartis | |
| Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. | NCT04794127 | Liposarcoma, My... Liposarcoma, De... Liposarcoma, Ro... | Trabectedin Pioglitazone Or... | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | NCT00400569 | Liposarcoma Leiomyosarcoma Fibrosarcoma Malignant Fibro... | Sunitinib Malat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
